US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

40.70

-0.6300-1.52%

Post-market: 40.700.0008+0.00%16:01 EDT

Volume:3.04M

Turnover:124.86M

Market Cap:263.49B

PE:26.24

High:41.34

Open:41.32

Low:40.70

Close:41.33

Loading ...

Overview Company News Filings

An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand

Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update

Trump's Chips War Has Left Intel's New CEO With a Near-Impossible Task. Here's Why and 5 Other Things to Know Today. -- Barrons.com

Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Roche Holding AG Rises Monday, Outperforms Market

SLDB Stock Rallies 60% in a Month: Here's What You Should Know

Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More

Roche Holding AG Falls Thursday, Outperforms Market

Genentech receives FDA acceptance for Gazyva sBLA

Roche Holding AG Rises Tuesday, Outperforms Market

Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Roche’s Genetech announces data from Phase III OUtMATCH study

Roche Holding AG Rises Tuesday, Underperforms Market

Swiss Market Index Hits All-Time High -- Market Talk

Roche Holding AG Falls Wednesday, Outperforms Market

European Pharma Sector Braces for Potential U.S. Tariffs -- Market Talk

Genetics Tools Face Fund Cuts -- Barron's

Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":40.7,"timestamp":1746561600000,"preClose":41.33,"halted":0,"volume":3043197,"hourTrading":{"tag":"盘后","latestPrice":40.7008,"preClose":40.7,"latestTime":"16:01 EDT","volume":9482,"amount":385924.60000000003,"timestamp":1746561663728},"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Post-Mkt","change":-0.63,"latestTime":"05-06 16:00:00 EDT Delay","open":41.32,"high":41.34,"low":40.7,"amount":124863074.17489992,"amplitude":0.015485,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1746576000000},"marketStatusCode":4,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.33,"volumeRatio":1.206256},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.206256,"shares":6474029800,"dividePrice":1.474122,"high":41.34,"amplitude":0.015485,"preClose":41.33,"low":40.7,"week52Low":30.03,"pbRate":"6.82","psRate":"3.47","week52High":44.31,"institutionHeld":0,"latestPrice":40.7,"eps":1.550894,"divideRate":0.036219,"volume":3043197,"delay":15,"ttmEps":1.550894,"open":41.32,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.66,"twentyDayClose":36,"sixtyDayClose":39.77},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2519873483","title":"An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup","url":"https://stock-news.laohu8.com/highlight/detail?id=2519873483","media":"Quartz","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519873483?lang=en_us&edition=fundamental","pubTime":"2025-03-14 17:00","pubTimestamp":1741942800,"startTime":"0","endTime":"0","summary":"Graphic: Images: Hims & Hers, Andrew Harnik, Spencer Platt / Staff, Stephen Maturen / Stringer. An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. senators have demanded, in a letter, that Health and Human Services  Secretary Robert F. Kennedy Jr. share details about several private dinners he attended with Donald Trump and healthcare executives at Mar-a-Lago. Novo Nordisk released clinical trial results on Monday for its potential Ozempic successor, but for the second time, it fell short of analysts’ expectations, disappointing Wall Street.Check out those stories and more pharmaceutical news highlights from this week.Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today. Hims & Hers will start selling generic liraglutide later this year. - Image: Hims & Hers ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ozempic-successor-falls-short-eli-090000158.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","SG9999014880.SGD","IE00BJJMRZ35.SGD","LLY","LU0225283273.USD","BK4585","GLP","BK4144","LU0158827948.USD","LU0385154629.USD","LU1623119135.USD","LU2602419157.SGD","SG9999014898.SGD","HHS","LU1093756168.USD","LU2361044865.SGD","LU1074936037.SGD","03165","LU2265009873.SGD","LU1267930730.SGD","LU1548497426.USD","SG9999001176.USD","API","LU0354030511.USD","LU1061106388.HKD","LU2023250504.SGD","LU2357305700.SGD","LU1059921491.USD","VKTX","LU1868837136.USD","LU2063271972.USD","LU0256863811.USD","BK4009","WBA","LU0208291251.USD","LU0154236417.USD","LU2028103732.USD","LU1989772840.SGD","LU0320765646.SGD","LU1917777945.USD","NVO","SGXZ51526630.SGD","LU2023251221.USD","LU0672654240.SGD","CVS","LU0321505439.SGD","LU0354030438.USD","LU2089283258.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2519863829","title":"NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2519863829","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519863829?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:23","pubTimestamp":1741886580,"startTime":"0","endTime":"0","summary":"Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 billion with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide. Roche’s latest deal increases competition in the obesity space.Roche Buys Rights to Obesity Drug From Zealand Pharma. Amylin drugs work similarly to the popular GLP-1 drugs ruling the obesity space. The GLP-1 space is dominated by NVO and Eli Lilly LLY, with their popular obesity injections, Wegovy  and Zepbound , respectively. Like GLP-1 drugs mimica naturally occurring hormone, GLP-1, to regulate blood sugar and promote weight loss, amylin drugs mimic another natural hormone amylin, which is secreted at the same time as insulin in response to food intake. Amylin drugs are being considered the next generation of obesity medicines after the current GLP-1 medicines.NVO’s stock has plunged 44.4% in the past year compared with a decrease of 5.2% for the industry.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nvo-stock-slips-4-roche-172300319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","LU1127390331.HKD","SG9999018865.SGD","LU2106854487.HKD","LU2491049909.HKD","BK4599","LU1548497426.USD","NVO","LU2237443622.USD","IE00BK4W5M84.HKD","SG9999001176.USD","LU0256863902.USD","LU2089984988.USD","BK4581","LU2602419157.SGD","LU0820561818.USD","SG9999015945.SGD","SG9999014898.SGD","LU2237443465.HKD","LU1868837136.USD","ZLDPF","IE00B4R5TH58.HKD","LU2112291526.USD","BK4007","SG9999015986.USD","SGXZ51526630.SGD","LU1291159041.SGD","LU1069344957.HKD","LU0466842654.USD","LU0385154629.USD","LU1720051108.HKD","LU0882574139.USD","LU2324357040.USD","LU0417517546.SGD","IE00BJLML261.HKD","VKTX","SG9999017495.SGD","LU2360106947.USD","LU2491050154.USD","03165","LU1551013425.SGD","LU2023250504.SGD","LU1093756168.USD","CDMO","LU1814569148.SGD","LU2237443549.SGD","LU2264538146.SGD","LU0061475181.USD","LU0058720904.USD"],"gpt_icon":1},{"id":"2519863822","title":"Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519863822","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519863822?lang=en_us&edition=fundamental","pubTime":"2025-03-14 01:05","pubTimestamp":1741885500,"startTime":"0","endTime":"0","summary":"This week, Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY announced a license and collaboration deal with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide. Pfizer PFE and partner Arvinas ARVN announced mixed phase III data for breast cancer therapy, vepdegestrant. J&J JNJ and partner Protagonist Therapeutics’ investigational targeted oral peptide, icotrokinra met the primary endpoint of clinical response in ulcerative colitis study.Here's a recap of the week’s most important stories.NVO's Novel Obesity Treatment Disappoints in Phase III Study. Novo Nordisk’sphase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide  and semaglutide .In the study, 61.9% of patients were given the highest dose of the drug.For the deal, Roche will make an upfro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-obesity-170500925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1732799900.SGD","BK4581","NVO","LU2089984988.USD","MBC","LU0058720904.USD","LU1894683264.USD","LU0054578231.USD","LU1032466523.USD","IE00BDGV0183.EUR","LU0345770993.USD","LU0053671581.USD","SG9999002232.USD","SG9999011175.SGD","JNJ","ZLDPF","LU1718418525.SGD","LU2505996509.AUD","LU0345769128.USD","LU2129689605.HKD","03165","LU0912757837.SGD","LU0466842654.USD","LU2112291526.USD","LU1261432733.SGD","ARVN","RHHBY","BK4559","LU0234570918.USD","LU1244550221.USD","SG9999001176.USD","IE00B42XCP33.USD","BK4599","ITT","LU1032955483.USD","LU1093756168.USD","IE00BGHQF631.EUR","LU1430594728.SGD","LU2602419157.SGD","LU0795875086.SGD","LU2430703095.HKD","PFE","SG9999003800.SGD","IE00BLSP4239.USD","IE00B19Z3581.USD","LU0345769631.USD","IE00B4R5TH58.HKD","LU0225284248.USD","BK4007","LU1066051811.HKD"],"gpt_icon":1},{"id":"2519875098","title":"Trump's Chips War Has Left Intel's New CEO With a Near-Impossible Task. Here's Why and 5 Other Things to Know Today. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2519875098","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519875098?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:58","pubTimestamp":1741863480,"startTime":"0","endTime":"0","summary":"It's possibly the hardest job in corporate America and Lip-Bu Tan is likely the best appointment. But it might be too much to ask Intel's new CEO to restore an icon of U.S. high-tech manufacturing to its former glory.Reviving Intel's chip-fabricating operations is the most difficult part of Tan's job, and one that chimes with the Trump administration's bid to revive American manufacturing. Secure supply chains are key to that goal and ensuring them for semiconductors is arguably the most important pillar -- beyond even steel or cars.However, President Donald Trump might make Tan's job even harder as he campaigns for a stop to the Chips Act -- which is set to grant up to $8.5 billion in direct funding to Intel as a big incentive to set up new factories across the U.S. Instead, the president hopes to achieve similar goals via the threat of tariffs, which he claims encouraged Taiwan Semiconductor Manufacturing -- the company that replaced Intel as the world's leading maker of advanced chi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4612","LU1712237335.SGD","LU2361044865.SGD","LU2089984988.USD","LU2491050071.SGD","US7Y.BOND","BK4592","LU0640476718.USD","BK4532","BK4581","RHHBY","LU0079474960.USD","LU1548497426.USD","LU0256863811.USD","LU1035775433.USD","SG9999014898.SGD","BK4512","IE00B2B36J28.USD","LU0234572021.USD","US3Y.BOND","LU2125154778.USD","LU0082616367.USD","LU0719512351.SGD","LU0109392836.USD","03165","LU0321505439.SGD","BK4007","LU0792757196.USD","US12M.BOND","BK4567","LU1917777945.USD","LU2458330243.SGD","US30Y.BOND","LU0345774631.USD","LU0965509101.SGD","US2Y.BOND","BK4566","LU2361044949.HKD","US5Y.BOND","LU2237438978.USD","INTC","US6M.BOND","US10Y.BOND","LU2095319765.USD","LU0471298777.SGD","SG9999001176.USD"],"gpt_icon":1},{"id":"2519098690","title":"Roche's Zealand Pharma Deal Signals Commitment to Obesity Drug Market -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2519098690","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519098690?lang=en_us&edition=fundamental","pubTime":"2025-03-13 15:46","pubTimestamp":1741851960,"startTime":"0","endTime":"0","summary":"0744 GMT - Faster price erosion and high rebates by insurers in the U.S. obesity market could overshadow Roche's long-term opportunities there, Morgan Stanley analysts say in a note. The Zealand Pharma deal to co-develop a weight-loss therapy with petrelintide allows the Swiss pharma giant to access a differentiated and current best-in-class obesity treatment and signals a commitment to the segment, they say. Morgan Stanley analysts expect petrelintide peak sales of 7 billion Swiss francs, which could support a consensus upgrade by 4%. Recent share-value increase suggest that the market has already priced in this. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","03165","LU2111349929.HKD","LU1989772840.SGD","BK4581","LU0225283273.USD","LU1732800096.USD","LU1720051017.SGD","LU1162221912.USD","LU0158827781.USD","LU0912757837.SGD","LU2133065610.SGD","LU1720051108.HKD","LU2357305700.SGD","LU2347655156.SGD","LU0314104364.USD","LU1074936037.SGD","LU2271345857.HKD","LU1548497426.USD","LU1668664300.SGD","LU0267386448.USD","LU0158827948.USD","LU2028103732.USD","RHHBY","BK4585","LU0795875169.SGD","LU0098860793.USD","LU2023251221.USD","BK4534","LU0006306889.USD","LU2089284900.SGD","LU1989772923.USD","LU0795875086.SGD","LU1732799900.SGD","LU2089283258.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","LU0971096721.USD","BK4007","BK4588","BK4516","LU1363072403.SGD","IE00BKVL7J92.USD","BK4127","BK4504","LU0106831901.USD"],"gpt_icon":0},{"id":"2518605218","title":"Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2518605218","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518605218?lang=en_us&edition=fundamental","pubTime":"2025-03-12 16:18","pubTimestamp":1741767480,"startTime":"0","endTime":"0","summary":"0818 GMT - Roche's deal to co-develop a weight-loss drug with Zealand Pharma makes sense as the Swiss pharma giant must expand its obesity therapy options to effectively compete in this field, Vontobel analyst Stefan Schneider says in a note. Roche entered a collaboration and licensing agreement with the Danish biotech company for its amylin analog petrelintide. It has only recently entered the weight-loss space through its acquisition of Carmot Therapeutics in December 2023. Vontobel expects the earliest launch for Roche's obesity assets in 2028 and anticipates risk-adjusted peak sales of 1.9 billion Swiss francs. Shares rise 3.7% to 307.50 Swiss francs. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2518742208","title":"Roche Holding AG Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2518742208","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518742208?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:16","pubTimestamp":1741626960,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 0.1% to CHF307.40 Monday on what proved to be an overall poor trading session for the stock market, with the Swiss SMI Index  falling 0.5% to 13,013.45.This was the stock's second consecutive day of gains.Trading volume was 1,340,946, compared to the 50-day average trading volume of 1,193,895.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2517087432","title":"SLDB Stock Rallies 60% in a Month: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2517087432","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517087432?lang=en_us&edition=fundamental","pubTime":"2025-03-07 22:13","pubTimestamp":1741356780,"startTime":"0","endTime":"0","summary":"Shares of Solid Biosciences SLDB have rallied 59.9% in the past month. The stock price increase was mainly due to positive initial data, announced in mid-Feb, fromthe early to mid-stage study of its next-generation gene therapy product candidate, SGT-003, for treating Duchenne muscular dystrophy .Interim biopsy data reported in the first three participants at day 90 showed an average microdystrophin expression of 110%, as measured by western blot, along with improvements in multiple biomarkers that are indicators of muscle health and resilience.In the past three months, shares of Solid Biosciences have gained 7.6% against the industry’s 1% decline.The initial data readout also showed encouraging early signals of potential cardiac benefit. SGT-003was well-tolerated in the first six DMD patients dosed. Adverse events were mostly mild to moderate in severity and consistent with those typically observed in AAV gene therapy.Currently,Sarepta TherapeuticsSRPT markets Elevidys as the only app","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sldb-stock-rallies-60-month-141300442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","IE00BFTCPJ56.SGD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","IE0009355771.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","LU0889565916.HKD","SLDB","SRPT","RHHBY","BK4539","BK4588","BIIB","FA","BK4139","LU0320765992.SGD","BK4007","03165","LU0234570918.USD","BK4535","BK4532","BK4130","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00BJT1NW94.SGD","IE00B894F039.SGD"],"gpt_icon":0},{"id":"2517643107","title":"Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2517643107","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517643107?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:09","pubTimestamp":1741352940,"startTime":"0","endTime":"0","summary":"This week, Bayer BAYRY announced its fourth-quarter and full-year 2024 results. AbbVie ABBV announced a licensing deal with Danish firm Gubra for an amylin-targeting obesity treatment, which marked the company’s entry into the obesity space. Novo Nordisk NVO announced that it is cutting the price of its popular obesity injection, Wegovy, for the uninsured following a similar move byrival Eli Lilly. J&J JNJ discontinued a phase III study on a candidate being evaluated as an adjunctive treatment for major depressive disorder . The FDA accepted Roche’s RHHBY application seeking expanded use of its lymphoma drug, Gazyva/Gazyvaro, for the treatment of lupus nephritis.Here's a recap of the week’s most important stories.Novo Nordisk is launching a new direct-to-patient online pharmacy called NovoCare, which will offer Wegovy at a discounted price of $499 per month, less than half of its listed price. This offer is for patients who do not have insurance coverage and pay by cash as well as thos","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-bayrys-q4-130900621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABBV","BK4592","LU0795875169.SGD","03165","LU0234572021.USD","LU1732800096.USD","LU0545039389.USD","LU0965508806.USD","LU1003077747.HKD","LU1261432733.SGD","LU1066053197.SGD","IE0004445239.USD","IE00B3PB1722.GBP","IE00B1BXHZ80.USD","RHHBY","LU1267930490.SGD","LU0949170772.SGD","IE00B2B36J28.USD","LU0689472784.USD","LU1093756325.SGD","LU0912757837.SGD","NVO","LU0965509010.AUD","SG9999015945.SGD","BK4581","IE00B42XCP33.USD","LU1221951129.SGD","IE0002141913.USD","LU1718418525.SGD","LU1914381329.SGD","LU1551013425.SGD","BK4585","LU2505996509.AUD","IE00BDGV0183.EUR","BK4007","LU2237443465.HKD","LU1196500208.SGD","IE00BJT1NW94.SGD","LLY","BK4566","LU0211327993.USD","LU0553294199.USD","BAYRY","IE00BJJMRZ35.SGD","LU0098860793.USD","LU2347655156.SGD","LU2087621335.USD","SG9999011175.SGD","BK4533","JNJ","LU1989771016.USD"],"gpt_icon":1},{"id":"2517419814","title":"Roche Holding AG Falls Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517419814","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517419814?lang=en_us&edition=fundamental","pubTime":"2025-03-07 01:16","pubTimestamp":1741281360,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  shed 0.2% to CHF302.70 Thursday on what proved to be an overall poor trading session for the stock market, with the Swiss SMI Index  falling 0.6% to 13,029.39.This was the stock's second consecutive day of losses.Roche Holding AG closed CHF2.20 short of its 52-week high of CHF304.90, which the company achieved on March 4, 2025.Trading volume was 1,224,862, compared to the 50-day average trading volume of 1,196,343.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AG","RHHBY"],"gpt_icon":0},{"id":"2517299997","title":"Genentech receives FDA acceptance for Gazyva sBLA","url":"https://stock-news.laohu8.com/highlight/detail?id=2517299997","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517299997?lang=en_us&edition=fundamental","pubTime":"2025-03-05 18:46","pubTimestamp":1741171578,"startTime":"0","endTime":"0","summary":"Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva for t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genentech-receives-fda-acceptance-for-gazyva-sbla?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genentech-receives-fda-acceptance-for-gazyva-sbla?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2517604688","title":"Roche Holding AG Rises Tuesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2517604688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517604688?lang=en_us&edition=fundamental","pubTime":"2025-03-05 01:17","pubTimestamp":1741108620,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 0.5% to CHF304.20 Tuesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss SMI Index  falling 1.2% to 13,006.74.This was the stock's third consecutive day of gains.Trading volume was 1,328,380, compared to the 50-day average trading volume of 1,177,540.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2516944666","title":"Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2516944666","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516944666?lang=en_us&edition=fundamental","pubTime":"2025-03-04 04:00","pubTimestamp":1741032000,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s  Committee for Medicinal Products for Human Use .The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma . The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.A final decision is expected in the coming months.Regeneron’s shares have lost 30.5% in the past year compared with the medical-biomedical genetics industry’s decline of 6.7%.Regeneron Pharmaceuticals Stock Price, Consensus and EPS Surprise. Regeneron Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Regeneron Pharmaceuticals, Inc. Quote. REGN’s oncology franchise got a boost with the European Commission","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-gets-positive-chmp-opinion-200000419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3B42.SGD","03165","BK4583","LU2106854487.HKD","BK4550","LU0889565916.HKD","LU0114720955.EUR","REGN","LU0109394709.USD","GILD","LU2237438978.USD","BK4568","LU0058720904.USD","LU1839511570.USD","LU2023250504.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU2362540622.SGD","BK4532","CHMP","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU1974910355.USD","LU0234570918.USD","LU1430594728.SGD","LU2087621335.USD","BK4087","LU2362541513.USD","RHHBY","BK4585","BK4566","BMRN","IE00BSNM7G36.USD","LU0289739699.SGD","LU0882574055.USD","FL","BK4094","LU0053666078.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","BK4139","BK4007","LU0320765992.SGD","LU1585245621.USD","IE00BKVL7J92.USD","LU1917777945.USD","LU1066051498.USD","LU2468319806.SGD","LU2089984988.USD"],"gpt_icon":0},{"id":"2516523142","title":"Roche’s Genetech announces data from Phase III OUtMATCH study","url":"https://stock-news.laohu8.com/highlight/detail?id=2516523142","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516523142?lang=en_us&edition=fundamental","pubTime":"2025-03-03 07:20","pubTimestamp":1740957614,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health-sponsored...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roches-genetech-announces-data-from-phase-iii-outmatch-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roches-genetech-announces-data-from-phase-iii-outmatch-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["III","RHHBY","BK4007","BK4134","03165"],"gpt_icon":0},{"id":"2514802012","title":"Roche Holding AG Rises Tuesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2514802012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514802012?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:16","pubTimestamp":1740503760,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  advanced 0.4% to CHF299.30 Tuesday on what proved to be an overall positive trading session for the stock market, with the Swiss SMI Index  rising 0.6% to 13,025.01.Trading volume was 1,283,944, compared to the 50-day average trading volume of 1,114,969.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2513742635","title":"Swiss Market Index Hits All-Time High -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2513742635","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513742635?lang=en_us&edition=fundamental","pubTime":"2025-02-24 19:24","pubTimestamp":1740396240,"startTime":"0","endTime":"0","summary":"1123 GMT - The Swiss Market Index reached an all-time high on Monday, surpassing the 13,000-point mark for the first time in its history. KitKat bars maker Nestle and flavor-and-fragrance company Givaudan helped lift the blue-chip index, which also got a boost from positive news from neighboring Germany, where election results pointed to a business-friendly environment that would kickstart economic growth after a couple of slack years. Luxury goods conglomerate Richemont, banking giant UBS and pharma major Roche are some of the Swiss companies that have delivered exceptional market performance so far this year, contributing to the index reaching an all-time high. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRGY","BK4202","BK4007","03165","CFRUY","BK4212","GVDNY","BK4109","RHHBY"],"gpt_icon":0},{"id":"2512875424","title":"Roche Holding AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2512875424","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512875424?lang=en_us&edition=fundamental","pubTime":"2025-02-20 01:16","pubTimestamp":1739985360,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  shed 0.1% to CHF294.70 Wednesday on what proved to be an overall negative trading session for the stock market, with the Swiss SMI Index  falling 0.7% to 12,798.52.Roche Holding AG closed CHF3.40 below its 52-week high of CHF298.10, which the company achieved on February 13, 2025.Trading volume was 1,126,639, compared to the 50-day average trading volume of 1,076,378.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2512817002","title":"European Pharma Sector Braces for Potential U.S. Tariffs -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2512817002","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512817002?lang=en_us&edition=fundamental","pubTime":"2025-02-19 19:12","pubTimestamp":1739963520,"startTime":"0","endTime":"0","summary":"1111 GMT - U.S. President Trump's plans for 25% tariffs on pharmaceutical imports could threaten the European sector, which relies heavily on the U.S. Swiss pharma giant Roche said it is closely monitoring U.S. legislative developments and assessing any potential impact these could have on its business. The company invested over 11 billion Swiss francs  in the U.S. over the last ten years and remains committed to invest there, the company added. GSK's chief executive officer Emma Walmsley said in a media call alongside results that the company will keep a close eye on how the fast-moving tariff situation will play out in the coming weeks. The British pharma company employs around 15000 people in the U.S. and has various R&D centres and manufacturing sites across the country. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU1829250122.USD","03165","BK4007","BK4532","BK4588","GSK.UK","GSK","RHHBY"],"gpt_icon":0},{"id":"2511640044","title":"Genetics Tools Face Fund Cuts -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2511640044","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511640044?lang=en_us&edition=fundamental","pubTime":"2025-02-15 10:30","pubTimestamp":1739586600,"startTime":"0","endTime":"0","summary":"Medical research fell under the hatchet of the Trump administration this week, and investors slashed the stocks of those who make lab equipment.The National Institutes of Health announced on Friday, Feb. 7, that it will cap its payments for the indirect costs of research, like support staff and costly lab equipment.Shares of gene-sequencing leader Illumina have fallen 17% to $101.50 since the announcement. Its smaller rivals  10X Genomics and Pacific BioSciences of California have lost 23% and 15%, respectively.Until now, the amount of a grant that could be spent on overhead -- known as \"indirect funds\" -- was negotiated for each grant. Indirect funds amounted to $9 billion, or 26%, of the $35 billion that NIH distributed in grants last year. NIH says it will now only allow 15% toward overhead. That would have reduced its last year's overhead payments to $5 billion from $9 billion.Medical research institutes and universities quickly warned that the cuts would devastate the search for c","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU1861558580.USD","LU1861559042.SGD","BK4535","03165","BK4588","TXG","BK4548","BK4585","ILMN","PACB","BK4121","BK4007","RHHBY"],"gpt_icon":1},{"id":"2511695412","title":"Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2511695412","media":"Zacks","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511695412?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:03","pubTimestamp":1739538180,"startTime":"0","endTime":"0","summary":"Here's a recap of the week’s most important stories.Novartis, along with private firm Blackstone Life Sciences, launched Anthos Therapeutics in 2019. Anthos Therapeutics was developing abelacimab under a licensing deal with Novartis. For the recent deal, Novartis will make an upfront payment of $925 million to Anthos Therapeutics, with the latter also being entitled to receive up to approximately$2.15 billionin potential milestone payments.FDA Approves Expanded Use of Pfizer’s Cancer Drug Adcetris. An interim analysisof a phase III study on Sanofi and J&J’s vaccine candidate for extraintestinal pathogenicE. coli, conducted by an independent data monitoring committee,revealed that the vaccine failed to demonstrate sufficient efficacy in preventing invasive E. colidisease. As a result, the study is being discontinued. The companies said that no safety signals have been identified in the study. Sanofi and J&J entered into a co-development deal for the vaccine in Oc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-nvs-abbv-130300054.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1989771016.USD","IE00BBT3K403.USD","IE00B4R5TH58.HKD","IE00BVYPNV92.GBP","LU0256863811.USD","LU0965509101.SGD","IE00BJT1NW94.SGD","LU0689472784.USD","LU0310799852.SGD","LU0203347892.USD","LU1585245621.USD","LU0058720904.USD","LU1003077747.HKD","LU1093756168.USD","RHHBY","BK4007","LU0225771236.USD","IE00BLSP4452.SGD","BK4566","03165","NVS","LU1989772840.SGD","SNY","LU1066053197.SGD","IE0002141913.USD","SG9999001176.SGD","LU0306807586.USD","LU0868494617.USD","LU1244550494.USD","LU2237443465.HKD","BK4592","ABBV","LU1496350171.SGD","LU2237443622.USD","LU0417517546.SGD","LU1551013342.USD","LU2089283258.USD","BK4585","LU1057294990.SGD","SG9999001440.SGD","PFE","LU1983299246.USD","IE0004445239.USD","IE00B3PB1722.GBP","LU0965509283.SGD","SGXZ57979304.SGD","LU0029864427.USD","BK4581","XLO","LU0545039389.USD","IE00B19Z3581.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1746072000000}}}